SkinMedica

About:

SkinMedica is focused on developing, acquiring, and commercializing products that improve the appearance of skin.

Website: http://www.skinmedica.com

Twitter/X: skinmedica

Top Investors: Apax Partners, Domain Associates, HealthCare Ventures, Montreux Equity Partners, Split Rock Partners

Description:

SkinMedica is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum® and hallmark TNS Recovery Complex®. The formulations in SkinMedica’s clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA® (eflornithine hydrochloride) Cream 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women. Colorescience Pro’s dermatologist recommended, high-performance cosmetics are formulated to remedy and camouflage specific skin concerns and protect skin from damaging effects of the sun and environment. Colorescience Pro’s luxury aesthetic makeup line is sold in the physician and medical spa channels.

Total Funding Amount:

$96.2M

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

Carlsbad, California, United States

Founded Date:

1999-01-01

Contact Email:

info(AT)skinmedica.com

Founders:

Richard Fitzpatrick, Scott Glenn

Number of Employees:

51-100

Last Funding Date:

2012-01-06

IPO Status:

Private

Industries:

© 2025 bioDAO.ai